602 / 1631
Pembrolizumab + Rituximab
•
Phase II, single arm study
•
Subjects received rituximab (375 mg/m
2
IV) on days 1, 8, 15, and 22 of
cycle 1 and pembrolizumab (200mg IV) every 3 weeks for up to 16 infusions
starting on day 2 of cycle 1.
Primary Endpoint
Overall Response Rate (ORR)
Nastoupil L. et al. ASCO 2017